5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition

Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition

Core Clinical Principle: The period of absolute marrow aplasia following conditioning chemotherapy is characterized by profound pancytopenia, severe gastrointestinal mucosal barrier breakdown, and intense catabolic stress. Optimizing supportive care—including stringent blood product irradiation to prevent fatal Transfusion-Associated GVHD, systematic assessment and management of oral mucositis, proactive nutritional stabilization, and stringent environmental isolation—is essential to reduce non-relapse mortality.

---

1. Transfusion Medicine in Hematopoietic Cell Transplantation

HCT recipients need a patient-specific transfusion plan shared by the transplant and transfusion services. Verify the indication, component modification, ABO phase, CMV strategy, thresholds, special matching, and the program’s start/stop timeline.

• Irradiation: Irradiate indicated cellular components to prevent transfusion-associated GVHD. Leukoreduction does not replace irradiation. The applicable dose specification is controlled by the blood supplier/transfusion service; nurses verify the irradiated designation and expiration rather than prescribing a nominal dose. Plasma and cryoprecipitate do not require irradiation. Granulocytes require special coordination and prompt administration.
• Leukoreduction: Reduces leukocytes, febrile nonhemolytic reactions, HLA alloimmunization, and transfusion-transmitted CMV risk. Some programs also require CMV-seronegative components for selected donor/recipient situations; follow transfusion-service policy.
• ABO transition: Major, minor, or bidirectional donor-recipient incompatibility changes red-cell and plasma selection across phases. Use the transfusion-service compatibility plan until donor-type erythropoiesis and isohemagglutinin issues resolve.
• Thresholds: Use the current order set, symptoms, bleeding, hemodynamics, cardiac/pulmonary disease, procedure, fever, platelet function, and goals. A hemoglobin threshold near 7 g/dL and prophylactic platelets near 10,000/mcL are common for stable adults, but they are not universal procedure or bleeding thresholds.
• Bedside safety: Complete identity and compatibility checks, baseline assessment, prescribed rate, reaction monitoring, and traceability. Stop a suspected reaction, maintain access as policy directs, assess ABCs/vitals, notify the transfusion service/prescriber, and send ordered specimens/component.

2. Platelet Refractoriness & Corrected Count Increment (CCI)

Platelet refractoriness occurs when a patient repeatedly fails to achieve the expected increase in circulating platelets following transfusion of an adequate platelet dose. It is formally evaluated using the Corrected Count Increment (CCI) calculated 1 hour post-transfusion:

$\text{CCI (cells/mcL} \cdot \text{m}^2 / 10^{11}) = \frac{(\text{Post-Transfusion Platelet Count} - \text{Pre-Transfusion Platelet Count}) \times \text{BSA (m}^2)}{\text{Number of Platelets Transfused } (10^{11})}$

(Note: A standard single-donor apheresis platelet unit contains approximately 3.0 x 10^11 platelets. If absolute platelet count is unavailable, the 1-hour count increment can be estimated).

• Diagnostic Cutoffs:
  • Normal Response: CCI > 7,500 to 10,000 /mcL·m2 / 10^11 at 1 hour post-transfusion.
  • Platelet Refractoriness: Defined as a 1-hour post-transfusion CCI < 5,000 to 7,500 on at least two consecutive transfusions.

+---------------------------------------------------------------------------------------------------+
|                         DIFFERENTIAL DIAGNOSIS OF PLATELET REFRACTORINESS                         |
|                                                                                                   |
|   NON-IMMUNE ETIOLOGIES (~80% of Cases)              IMMUNE-MEDIATED ETIOLOGIES (~20% of Cases)   |
|   * Active high fever / severe sepsis                * Anti-HLA Class I Alloantibodies (most common)|
|   * Splenomegaly (splenic sequestration)             * Anti-Human Platelet Antigen (HPA) Antibodies|
|   * Active major bleeding / consumption              * ABO Incompatibility (minor direction)      |
|   * Disseminated Intravascular Coagulation (DIC)     * Autoantibodies                             |
|   * Sinusoidal Obstruction Syndrome (SOS/VOD)                                                     |
|   * Medications (Amphotericin B, Vancomycin, Ganciclovir)                                         |
|                                                                                                   |
|   MANAGEMENT OF IMMUNE-MEDIATED REFRACTORINESS:                                                   |
|   1. Screen patient serum for Panel Reactive Antibodies (PRA) and Anti-HLA Class I antibodies.    |
|   2. Order Crossmatched Platelets (serologically crossmatched against recipient serum).           |
|   3. Order HLA-Matched Single-Donor Apheresis Platelets (A-match or B-match from donor registry). |
+---------------------------------------------------------------------------------------------------+

---

3. Oral Mucositis: Assessment, Prevention and Care

Conditioning chemotherapy and radiation can injure basal epithelium and submucosa, amplify inflammatory signaling, produce painful ulceration, and permit microbial translocation. Healing often accompanies epithelial and marrow recovery, but visible injury, pain, infection, bleeding and ability to eat do not always improve together.

The WHO scale combines examination and oral intake: grade 1 is soreness/erythema; grade 2 has ulceration while solid food remains possible; grade 3 limits the patient to liquids; and grade 4 makes oral alimentation impossible. Record the scale used and trend pain, secretions, swallowing, intake, weight and hydration.

Use basic oral care with a soft brush, bland rinses, lip care, regular assessment, and avoidance of irritating tobacco/alcohol products or unverified compounded rinses. Oral cryotherapy is recommended for prevention with high-dose melphalan when feasible; timing follows the regimen protocol and aspiration/sensitivity risk. Photobiomodulation is used in centers with an evidence-based HCT protocol and trained equipment.

For established mucositis, provide individualized topical and systemic analgesia, hydration, nutrition, antiemetics, and infection assessment. Patient-controlled opioid analgesia may be appropriate for severe pain, but agent and route depend on organ function, sedation risk, goals, and monitoring. New fever, bleeding, inability to handle secretions, airway concern, uncontrolled pain, or inadequate intake requires escalation.

4. Nutritional Support in Aplasia & Refeeding Syndrome Prevention

Transplant patients experience extreme hypercatabolism driven by conditioning, fever, and cytokine storms. Severe mucositis, intractable nausea, vomiting, and diarrhea often compromise voluntary oral intake for 2 to 4 weeks.

Enteral Nutrition (EN) vs. Total Parenteral Nutrition (TPN)

• Enteral Nutrition (Preferred): Feeding via nasogastric or small-bore post-pyloric tube maintains gut mucosal trophism, preserves tight junctions, and reduces bacterial translocation and systemic bloodstream infections compared to TPN.
• Total Parenteral Nutrition (TPN): Indicated when severe Grade 3–4 gastrointestinal mucositis, paralytic ileus, intractable vomiting, severe typhlitis, or high-volume diarrhea (> 1,000 mL/day) prevents safe enteral delivery. Parenteral nutrition requires compatible dedicated access when specified, glucose/liver/triglyceride and catheter monitoring, and the correct filter for its formulation under pharmacy policy.

Refeeding Syndrome Prevention

After prolonged poor intake, carbohydrate reintroduction increases insulin and shifts phosphate, potassium and magnesium intracellularly while expanding sodium/water retention. Falling phosphate is a key warning; weakness, edema, arrhythmia, delirium, seizure or respiratory failure can follow.

Identify risk before feeding, check and correct electrolytes, provide thiamine as ordered, begin calories conservatively, and advance with frequent clinical and laboratory reassessment. Exact starting calories, thiamine dose and monitoring interval depend on severity and the nutrition protocol. If dangerous electrolyte or fluid changes develop, slow or pause advancement, replace deficits and escalate rather than continuing the original goal.

5. Environmental and Line Safety

Use a protective environment with positive pressure, HEPA filtration and construction-dust controls for the inpatient populations specified by current HCT standards and facility policy. Apply hand hygiene and transmission-based precautions, exclude soil/plants where indicated, and teach exposure avoidance without implying that every outpatient needs isolation.

Central-line care follows the device, dressing and antiseptic product instructions and the current bundle. Inspect the site and necessity, use aseptic access and vigorous hub disinfection for the policy-defined time, change loose/soiled dressings promptly, and escalate pain, drainage, erythema, fever, breakage or migration. Fixed seven-day or 15-second values should be verified against the actual product and policy.